



COLORADO

Department of Health Care
Policy & Financing

AGENDA
Pharmaceutics & Therapeutics Committee
Department of Health Care Policy & Financing

Zoom Webinar:

https://primetherapeutics.zoom.us/webinar/register/WN_fIUwz3bHTy-4yekfAohYxw

Tuesday, April 8, 2025, 1:00-5:00 P.M. MST

1. Committee Member Introductions

2. Unfinished Business and General Orders

Approval of minutes from January 07, 2025 P&T meeting

Updates from January 07, 2025 P&T Meeting

3. New Business

Updates from the Prior Authorization Call Center

4. Drug Classes Up for Review

Review of Buprenorphine, Injectable

Review of Tetracyclines

Review of PAH Therapies

PDEIs, Endothelin Antagonists, Prostanoids & Guanylate Cyclase Stimulators

Review of Statins & Combinations

Movement Disorder Agents

Review of Acne Agents, Topical

Review of Immunomodulators, Topical

Atopic Dermatitis, Antineoplastics & Other Agents

Review of Anti-Emetics - Oral & Non-Oral

Review of H. Pylori Treatments

Review of Proton Pump Inhibitors

Mass review drug classes:

- Alpha-Blockers
- Beta-Blockers - Single Agent, Anti-Arrhythmics & Combinations
- Calcium Channel Blockers - DHPs & Non-DHPs
- Angiotensin Converting Enzyme (ACE) Inhibitors & Combinations
- Angiotensin Receptor Blockers (ARBs) & Combinations
- Renin Inhibitors & Combinations
- Lipotropics - Bile Acid Sequestrants, Fibrates & Other Agents
- Acne Agents, Oral Isotretinoin



- Anti-Psoriatics - Oral & Topical
- Rosacea Agents
- Topical Steroids - Low, Medium, High & Very High Potency
- Bile Salts
- GI Motility, Chronic
- Hemorrhoidal, Anorectal, and Related Topical Anesthetic Agents
- Pancreatic Enzymes
- Non-Biologic Ulcerative Colitis - Oral & Rectal
- Anticoagulants - Oral & Parenteral
- Anti-Platelets
- Colony Stimulating Factors
- Erythropoiesis Stimulating Agents

Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass Review drug classes will only include:

- Overview for each Drug Class, including market share overview

Presentations:

- Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical testimony that will be presented for P&T Committee dissemination.
- Advance notice requests to present and/or written public comments can be submitted to Erik Hamel, Pharmacist Account Executive, erik.hamel@primetherapeutics.com and carbon copy: Greg Miller, PDL & Clinical Strategy Pharmacist, greg.l.miller@state.co.us. Once approved, public comments will be distributed to P&T Committee Members.
- Requests and public comment summaries are due by **April 1st, 2025 by 5pm MST**.

5. Adjourn

Upcoming Meeting Date: July 8, 2025.

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the [504/ADA Coordinator](#) or hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

